Search

Your search keyword '"Michael Choi"' showing total 219 results

Search Constraints

Start Over You searched for: Author "Michael Choi" Remove constraint Author: "Michael Choi"
219 results on '"Michael Choi"'

Search Results

1. Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells

2. A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter’s Transformation

3. 11 b 200 MS/s 28‐nm CMOS 2b/cycle successive‐approximation register analogue‐to‐digital converter using offset‐mismatch calibrated comparators

4. Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study

5. Targeting Glycolysis in Alloreactive T Cells to Prevent Acute Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia Effect

6. Understanding Preferences for Lifestyle-Focused Visual Text Messages in Patients With Cardiovascular and Chronic Respiratory Disease: Discrete Choice Experiment

7. Application of Mathematical Models to Determine the Feasibility of Amorphous Drug Layering in Pan Coaters

8. Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy

9. Inter-Rater Agreement in the Assessment of Video Recordings of Eye Drop Instillation by Glaucoma Patients.

12. Flavin-Dependent Thymidylate Synthase as a New Antibiotic Target

28. A 72GS/s, 8-bit DAC-based Wireline Transmitter in 4nm FinFET CMOS for 200+Gb/s Serial Links.

30. An 8-bit 56GS/s 64x Time-Interleaved ADC with Bootstrapped Sampler and Class-AB Buffer in 4nm CMOS.

34. Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke

35. Supplementary Fig 2 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

36. Supplementary Fig 1 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

37. Supplementary Table 5 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

38. Supplementary Table 2 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

39. Data from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

40. Supplementary Table 4 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

41. Supplementary Table 1 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

42. Supplementary Table 6 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

43. Supplementary Table 3 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

44. Supplemental Figure 2 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

45. Data from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

46. Supplemental Figure 1 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

47. Supplementary Fig 3 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

48. Supplementary Table 2 from HIF Induces Human Embryonic Stem Cell Markers in Cancer Cells

49. Supplementary Table 5 from HIF Induces Human Embryonic Stem Cell Markers in Cancer Cells

50. Supplementary Methods, Figures 1-11, Table Legends 1-7 from HIF Induces Human Embryonic Stem Cell Markers in Cancer Cells

Catalog

Books, media, physical & digital resources